NRX Pharmaceuticals, Inc. (NRXP)

NRXP's stock price has experienced significant fluctuations over the past six months. From January 13, 2025, to January 9, 2026, the share price declined by 54.79%, but saw a 177% gain in the three months leading up to January 28, 2025, driven by increased retail interest. Key events impacting the stock price include the elimination of all balance sheet debt on December 18, 2025, and a partnership with neurocare Group AG on January 5, 2026. The company has been actively pursuing FDA approval for its preservative-free intravenous ketamine formulation (NRX-100) and is preparing to file an NDA for accelerated approval of NRX-101, with an anticipated 2025 PDUFA date expected for NRX-101, and NRX-100 anticipated to be offered to the marketplace by early 2026, contingent on FDA approval. The company reported its Q3 2025 earnings on November 17, 2025, posting an earnings per share (EPS) of -$0.27, which missed analysts' expectations, and the next earnings report is scheduled for March 13, 2026. NRX Pharmaceuticals has split its stock once.

Based on available data, only 7 years of historical information are present for NRXP, which is considered insufficient to create a fully reliable seasonal profile for its products and services. However, an analysis of seasonal charts over the past 7 years suggests a "Buy Date" of November 10 and a "Sell Date" of March 1, which has resulted in a geometric average return of 9.7% above the S&P 500 Total Return Index. This seasonal timeframe has shown positive results in 5 out of 7 periods and significantly outperforms the stock's relative buy-and-hold performance over the same period. It is important to note that this seasonal timeframe correlates poorly with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4.

NRX Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for life-threatening neurological and psychiatric conditions, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. The company's major product candidates include NRX-101, an oral antidepressant targeting suicidal bipolar depression; NRX-100, an intravenous ketamine formulation for suicidal depression; ZYESAMI, an application for COVID-related respiratory failure; and ZICLESOME™, a novel NMDA receptor antagonist for severe depression and other neuropsychiatric indications. The company's strategy involves leveraging neuroscience and drug development expertise, focusing on targeted therapeutic approaches, and advancing compounds with established safety profiles into new neurological and inflammatory conditions.

NRX Pharmaceuticals, Inc. is based in Radnor, Pennsylvania, and headquartered in Wilmington, Delaware, USA. The company has initiated multiple proof-of-concept studies for its pipeline, including Ifenprodil, in the United States and Europe. Through its wholly-owned subsidiary, HOPE Therapeutics, NRx Pharmaceuticals is establishing a nationwide network of interventional psychiatry clinics in the US, which will integrate with existing neurocare clinics.

In the past year, NRx Pharmaceuticals has maintained a "Moderate Buy" consensus rating from analysts, with 4 buy ratings, 1 hold rating, and 1 sell rating. The company's average rating score is 2.50, and it has a consensus price target of $36.75, representing a significant upside from its current price. NRx Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat and ranked 391st out of 914 stocks in the medical sector. Events that have positively affected the company's reputation include the elimination of all balance sheet debt in December 2025, the partnership with neurocare Group AG in January 2026, progress in drug development, and increased retail interest and bullish sentiment on platforms like Stocktwits in early 2025.

The ownership structure of NRX Pharmaceuticals (NRXP) stock is a mix of institutional, retail, and individual investors. Approximately 8.72% to 14.10% of the company's stock is held by institutional investors, 13.43% by insiders, and 72.47% by public and individual investors. Major institutional owners and shareholders include Anson Funds Management LP, Vanguard Group Inc, AdvisorShares Investments LLC, PSIL - AdvisorShares Psychedelics ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Marshall Wace, LLP, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, UBS Group AG, and Renaissance Technologies Llc. Chaim Hurvitz is noted as owning the most shares among individual investors.